Celcuity Inc. (NASDAQ:CELC) saw a 167% surge in stock price on Monday, closing at $36.79 per share due to positive results in a breast cancer treatment trial. The three-drug combination reduced risk progression and death by 76% compared to fulvestrant alone, boosting chances for FDA approval by year-end. Leerink set a $60 price target for CELC with an “outperform” rating.

Read more at Yahoo Finance: Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial